New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
https://doi.org/10.15829/1728-8800-2019-6-80-87
Abstract
Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that combination therapy with PAH-specific medications can significantly inhibit the development of the disease. Therefore, in modern guidelines, combination therapy is considered as a treatment standard for a significant proportion of patients with PAH. This publication presents a modern view of the selexipag practical using in early combination therapy in patients with PAH.
About the Authors
N. V. Ilyin
Republican Hospital № 1 — National Center of Medicine
Russian Federation
Yakutsk.
Russian Federation
Yakutsk.
K. I. Ivanov
Republican Hospital № 1 — National Center of Medicine
Russian Federation
Yakutsk.
Russian Federation
Yakutsk.
T. V. Martynyuk
National Medical Research Center of Cardiology
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119. doi:10.1093/eurheartj/ehv317.
2. Chazova IE, Arkhipova OA, Martynyuk TV, et al. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh. 2019;91(1):24-31. (In Russ.)
3. Duggan ST, Keam SJ, Burness CB. Selexipag: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2017;17(1):73-80. doi:10.1007/s40256-016-0209-9.
4. Instruction for the medical use of the medicine Ventavis. Registration certificate ЛСР-005775/10. (In Russ.)
5. Instruction for the medical use of the medicine Upbravi. Registration certificate LP-005577. (In Russ.)
6. State Register of Medicines (In Russ.)
7. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874-80. doi:101183/09031936.00213711.
8. Noel ZR, Kido K, Macaulay TE. Selexipag for the treatment of pulmonary arterial hypertension. American Journal of Health System Pharmacy. 2017;74(15):1135-41. doi:10.2146/ajhp160798.
9. Sitbon O, Channick R, Chin KM, et al; for the GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522- 33. doi:10.1056/NEJMoa1503184.
10. Coghlan G, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018;18(1):37-47. doi:10.1007/s40256-017-0262-z7.
11. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834-44. doi: 10.1056/NEJMoa1413687.
12. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50:1602493. doi:10.1183/13993003.02493-2016.
13. Beghetti M, Channick RN, Chin KM, et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019;21(3):352-9. doi:10.1002/ejhf.1375.
Review
For citations:
Ilyin N.V., Ivanov K.I., Martynyuk T.V. New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag. Cardiovascular Therapy and Prevention. 2019;18(6):80-87. (In Russ.) https://doi.org/10.15829/1728-8800-2019-6-80-87
Views:
1133
Email this article 
